MiMedx Group, Inc. (NASDAQ:MDXG) Insider Sells $14,142.36 in Stock

MiMedx Group, Inc. (NASDAQ:MDXG - Get Free Report) insider Kimberly Maersk-Moller sold 1,759 shares of the firm's stock in a transaction on Monday, March 17th. The stock was sold at an average price of $8.04, for a total value of $14,142.36. Following the transaction, the insider now directly owns 309,077 shares of the company's stock, valued at approximately $2,484,979.08. This represents a 0.57 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Kimberly Maersk-Moller also recently made the following trade(s):

• On Thursday, March 13th, Kimberly Maersk-Moller sold 4,106 shares of MiMedx Group stock. The stock was sold at an average price of $7.89, for a total value of $32,396.34.
• On Friday, February 28th, Kimberly Maersk-Moller sold 2,111 shares of MiMedx Group stock. The shares were sold at an average price of $8.40, for a total value of $17,732.40.

MiMedx Group Trading Up 2.0 %

Shares of NASDAQ:MDXG traded up $0.16 during midday trading on Monday, reaching $8.10. The company's stock had a trading volume of 528,318 shares, compared to its average volume of 693,587. MiMedx Group, Inc. has a fifty-two week low of $5.47 and a fifty-two week high of $10.14. The company has a debt-to-equity ratio of 0.10, a quick ratio of 3.53 and a current ratio of 4.10. The firm has a 50 day moving average price of $8.36 and a two-hundred day moving average price of $7.88. The firm has a market capitalization of $1.19 billion, a price-to-earnings ratio of 14.73 and a beta of 1.97.

Remove Ads

MiMedx Group (NASDAQ:MDXG - Get Free Report) last posted its quarterly earnings results on Wednesday, February 26th. The company reported $0.07 earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of $0.07. The firm had revenue of $92.91 million for the quarter, compared to analysts' expectations of $89.42 million. MiMedx Group had a return on equity of 26.21% and a net margin of 23.86%. As a group, analysts forecast that MiMedx Group, Inc. will post 0.3 earnings per share for the current year.

Institutional Investors Weigh In On MiMedx Group

A number of large investors have recently bought and sold shares of MDXG. IMG Wealth Management Inc. bought a new position in shares of MiMedx Group during the 4th quarter worth about $28,000. Virtus Fund Advisers LLC acquired a new position in MiMedx Group during the 4th quarter worth approximately $35,000. Van ECK Associates Corp bought a new position in MiMedx Group in the fourth quarter worth approximately $40,000. Tower Research Capital LLC TRC grew its stake in MiMedx Group by 77.4% in the fourth quarter. Tower Research Capital LLC TRC now owns 6,501 shares of the company's stock valued at $63,000 after acquiring an additional 2,837 shares during the period. Finally, Point72 DIFC Ltd increased its holdings in shares of MiMedx Group by 127.6% during the third quarter. Point72 DIFC Ltd now owns 7,626 shares of the company's stock valued at $45,000 after acquiring an additional 4,275 shares in the last quarter. 79.15% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Separately, Cantor Fitzgerald restated an "overweight" rating and issued a $13.00 price target on shares of MiMedx Group in a research report on Thursday, February 27th.

About MiMedx Group

MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins.